Abstract:An enzymatic method has been successfully established enabling the generation of partially base-modified RNA (previously named RZA) constructs, in which all G residues were replaced by isomorphic fluorescent thienoguanosine ( th G) analogs, as well as fully modified RZA featuring th G, 5-bromocytosine, 7-deazaadenine and 5-chlorouracil. The transcriptional efficiency of emissive fully modified RZA was found to benefit from the use of various T7 RNA polymerase variants. Moreover, d th G could be incorporated into PCR products by Taq DNA polymerase together with the other three base-modified nucleotides. Notably, the obtained RNA products containing th G as well as th G together with 5-bromocytosine could function as effectively as natural sgRNAs in an in vitro CRISPR-Cas9 cleavage assay. N 1 -Methylpseudouridine was also demonstrated to be a faithful non-canonical substitute of uridine to direct Cas9 nuclease cleavage when incorporated in sgRNA. The Cas9 inactivation by 7-deazapurines indicated the importance of the 7-nitrogen atom of purines in both sgRNA and PAM site for achieving efficient Cas9 cleavage. Additional aspects of this study are discussed in relation to the significance of sgRNA–protein and PAM–-protein interactions that were not highlighted by the Cas9–sgRNA–DNA complex crystal structure. These findings could expand the impact and therapeutic value of CRISPR-Cas9 and other RNA-based technologies. Nucleobase modifications enzymatically incorporated into the CRISPR-Cas9 system revealed the tolerance of Cas9 to m1Ψ- and fluorescent th G-modified sgRNA and requirements for PAM recognition. With the advent of CRISPR-Cas9 gene editing, we now have to hand a simple two-component system amendable to silencing and knock-in editing effectively any gene. Yet we must not forget that the implications of immunotoxicity along with the poor stability and specificity of canonical nucleic acids hold enormous challenges for in vivo applications, especially in gene therapy. Our study endorses the feasibility of the enzymatic approach to incorporate nucleobase modifications into the CRISPR-Cas9 system unveiling the tolerance of Cas9 to N 1 -methylpseudouridine (m1Ψ)- and emissive thienoguanosine ( th G)-modified sgRNA as well as thus far uncharted structural requirements for ensuring proper PAM recognition.

Regulation of CRISPR-Cas12a system by methylation and demethylation of Guide RNA

Regulation of the CRISPR-Cas12a System by Methylation and Demethylation of Guide RNA.

Targeted Manipulation of Cellular RNA m6A Methylation at theSingle-Base Level br

Targeted Manipulation of M6a RNA Modification Through CRISPR-Cas-based Strategies.

Chemical Modification and Transformation Strategies of Guide RNAs in CRISPR‐Cas9 Gene Editing Systems

Chemical Control of CRISPR Gene Editing via Conditional Diacylation Crosslinking of Guide RNAs

Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system

Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications

Programmable RNA N 6 -methyladenosine editing by CRISPR-Cas9 conjugates

Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing

CRISPR/Cas9-mediated epigenetic editing tool: An optimized strategy for targeting de novo DNA methylation with stable status via homology directed repair pathway

CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids

Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.

CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation

Conditional Control of RNA-guided Nucleic Acid Cleavage and Gene Editing

Unmodificated stepless regulation of CRISPR/Cas12a multi-performance

Enhanced control of RNA modification and CRISPR-Cas activity through redox-triggered disulfide cleavage

Modulating CRISPR/Cas9 genome-editing activity by small molecules

Reducing CRISPR-Cas9 off-target effects by optically controlled chemical modifications of guide RNA

Targeted RNA m 6 A Editing Using Engineered CRISPR-Cas9 Conjugates.

Aptazyme-mediated Direct Modulation of Post-Transcriptional Sgrna Level for Conditional Genome Editing and Gene Expression.